These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1768 related items for PubMed ID: 19884556

  • 1. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 10; 27(35):5924-30. PubMed ID: 19884556
    [Abstract] [Full Text] [Related]

  • 2. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.
    Cancer Chemother Pharmacol; 2011 Oct 10; 68(4):1045-55. PubMed ID: 21340604
    [Abstract] [Full Text] [Related]

  • 3. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.
    Eur J Cancer; 2010 Jul 10; 46(11):1997-2009. PubMed ID: 20413299
    [Abstract] [Full Text] [Related]

  • 4. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.
    J Clin Oncol; 2009 Jun 01; 27(16):2622-9. PubMed ID: 19398573
    [Abstract] [Full Text] [Related]

  • 5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul 01; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 7. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.
    Clin Colorectal Cancer; 2011 Dec 10; 10(4):325-32. PubMed ID: 21729677
    [Abstract] [Full Text] [Related]

  • 8. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec 10; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 10; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 10. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.
    Cancer Treat Rev; 2010 Nov 10; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N, Lahti L, Borze I, Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P, Knuutila S, Sarhadi VK.
    Cancer Genet; 2012 Nov 10; 205(11):545-51. PubMed ID: 23098991
    [Abstract] [Full Text] [Related]

  • 12. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N, Yamada Y, Taniguchi H, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y.
    Arch Med Res; 2014 Jul 10; 45(5):366-74. PubMed ID: 24830936
    [Abstract] [Full Text] [Related]

  • 13. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G.
    J Cancer Res Clin Oncol; 2014 May 10; 140(5):737-48. PubMed ID: 24595598
    [Abstract] [Full Text] [Related]

  • 14. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A.
    Cancer Treat Rev; 2009 May 10; 35(3):262-71. PubMed ID: 19117687
    [Abstract] [Full Text] [Related]

  • 15. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
    Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Sugiyama M, Watanabe T.
    Oncol Rep; 2014 Jul 10; 32(1):57-64. PubMed ID: 24839940
    [Abstract] [Full Text] [Related]

  • 16. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
    Genet Med; 2013 Jul 10; 15(7):517-27. PubMed ID: 23429431
    [Abstract] [Full Text] [Related]

  • 17. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
    Tural D, Batur S, Erdamar S, Akar E, Kepil N, Mandel NM, Serdengeçti S.
    Tumour Biol; 2014 Feb 10; 35(2):1041-9. PubMed ID: 23996432
    [Abstract] [Full Text] [Related]

  • 18. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
    Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.
    Clin Colorectal Cancer; 2012 Jun 10; 11(2):143-50. PubMed ID: 22285706
    [Abstract] [Full Text] [Related]

  • 19. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK, Lin AJ, Lin CC, Lan YT, Yang SH, Li AF, Chang SC.
    J Surg Oncol; 2011 Nov 01; 104(6):661-6. PubMed ID: 21671463
    [Abstract] [Full Text] [Related]

  • 20. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A.
    Int J Cancer; 2015 Jan 01; 136(1):83-90. PubMed ID: 24806288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 89.